Literature DB >> 17230225

Absence of JAK-2V617F point mutations in multiple myeloma.

Q Huang, X Li, W Chen, L M Weiss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17230225     DOI： 10.1038/sj.leu.2404551

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  3 in total

1.  High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation.

Authors:  T Nishihori; Y Hassoun; L Zhang; K Shain; M Alsina; M A Kharfan-Dabaja
Journal:  Bone Marrow Transplant       Date:  2013-08-12       Impact factor: 5.483

2.  Molecular Diagnostics with Laboratory Finding in Patients with Myeloproliferative Neoplasms.

Authors:  Zahra Makani; Sina Mirzaahmadi; Marzieh Motallebi; Abolfazl Movafagh
Journal:  Iran J Public Health       Date:  2017-11       Impact factor: 1.429

3.  The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.

Authors:  Barry Paul; Yue Zhao; Gavin Loitsch; Daniel Feinberg; Parker Mathews; Ian Barak; Megan Dupuis; Zhiguo Li; Lindsay Rein; Endi Wang; Yubin Kang
Journal:  Cancer Med       Date:  2020-07-06       Impact factor: 4.452
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.